Abacavir market continues to show steady pharmaceutical and regulatory activity, primarily driven by its use in HIV-1 treatment regimens, especially in pediatric and fixed-dose combination therapies. Recent developments from 2024 to 2025 highlight expanding access to generic formulations and increased regulatory approvals supporting global HIV treatment programs.
In January 2025, Lupin Limited announced that it received tentative approval from the U.S. FDA for its Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension (60 mg/5 mg/30 mg) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). This approval allows the company to market a generic equivalent of Triumeq PD® Tablets for Oral Suspension, developed by ViiV Healthcare. The product is intended for pediatric HIV-1 patients aged at least 3 months and weighing at least 6 kg, offering a once-daily single-pill regimen designed to improve adherence and treatment outcomes. The manufacturing of this formulation is planned at Lupin’s Nagpur facility in India, and the supply is targeted toward low- and middle-income countries, strengthening global HIV care accessibility.
Earlier, in December 2024, Lupin also received tentative approval from the U.S. FDA for the same Abacavir-based fixed-dose combination (Abacavir 60 mg / Dolutegravir 5 mg / Lamivudine 30 mg). This earlier approval similarly supported a generic version of Triumeq PD® Oral Suspension and marked an important step in expanding affordable pediatric HIV treatment options. September 2024 data, the reference listed drug recorded approximately USD 1.3 million in annual U.S. sales, reflecting a niche but important segment in pediatric HIV therapy.
Both approvals are part of Lupin’s broader strategy to strengthen its HIV portfolio and expand its presence in regulated generics markets. The company emphasized its commitment to delivering affordable, high-quality antiretroviral therapies globally, particularly for underserved populations. With these developments, Abacavir-containing regimens continue to play a crucial role in combination therapies for HIV-1, especially in pediatric care where dosing flexibility and suspension formulations are essential.
Overall, the Abacavir market trend (2024–2025) is characterized by increased FDA activity in generic approvals, growing focus on pediatric HIV formulations, and expansion of access programs such as PEPFAR. These factors collectively support sustained demand for Abacavir-based combinations, while also encouraging competitive generic entry into the U.S. and global HIV treatment markets.
